Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, Active Motif to Collaborate on FPGA-Based Analysis of Sequencing Data

NEW YORK (GenomeWeb News) – Invitrogen and Active Motif said today that they will collaborate in exploring the use of field programmable gate array technology for analyzing next-generation sequencing data.
 
Active Motif markets TimeLogic's biocomputing systems, which couple an FPGA accelerator with optimized genomics algorithms to rapidly compare novel sequences to databases of well-characterized genes.
 
The alliance is aimed at exploring “ways in which [Active Motif’s] technology can speed the processing of data directly from next-generation sequencing instruments, and to assess the physical requirements — such as power consumption, cooling, data transfer, and space constraints — that an optimal computational solution for research and clinical teams would require,” Joe Fernandez, CEO of Carlsbad, Calif.-based Active Motif, said in a statement.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.